Introduction {#s1}
============

Quantification of left ventricular (LV) contractility is critical to the detection and management of many cardiovascular diseases, including ischemic heart disease, valvular disorders, and heart failure. The gold standard for deriving load-independent parameters characterizing LV contractility and diastolic relaxation relies on specialized and rarely performed direct invasive measurements of LV pressures (Zile et al., [@B58]; Westermann et al., [@B55]). Among measurements that can be made from those data, the slope of the end-systolic pressure-volume relationship (ESPVR), defined as the maximal elastance of the ventricle, is a proven metric of systolic contractility (Muthurangu and Razavi, [@B31]). Similarly, the end-diastolic pressure volume relationship (EDPVR) is a measure of the ventricular compliance during diastole (Burkhoff et al., [@B6]). Extrapolation of these relationships to the entire cardiac cycle leads to the concept of time-varying elastance (Suga et al., [@B46]), defined as the ratio of instantaneous ventricular pressure to volume. The time-varying elastance can be used to characterize the contractile state of the ventricle at each time point during the cardiac cycle.

The clinical applicability of pressure-volume relationships has been hindered by the difficulty of obtaining these measurements non-invasively. Different imaging methods have been used to provide the volume information, but still require invasive LV pressure measurements. In a study by Schmitt et al. ([@B39]), invasive LV pressure data were combined with two-dimensional phase-contrast MRI (2D PC-MRI) data for assessing the LV ESPVR and EDPVR in swine. In conventional clinical practice, the inability to make these accurate measurements has led to substitution with load-dependent surrogate markers of LV systolic and diastolic function such as ejection fraction and mitral inflow patterns derived from Doppler echocardiography and 2D PC-MRI (el-Said et al., [@B15]; Iwakami et al., [@B22]; Paelinck et al., [@B35]). The limitations in accuracy and performance of load-dependent measures for defining actual LV contractility and compliance are well recognized, and a source of uncertainty and potential error in patient care (Thomas and Popović, [@B48]).

The response of LV contractility and relaxation across a physiologically relevant range of load and heart rate is more predictive of disease than isolated resting measurements. Clinically, stress testing to expose abnormalities in cardiac function is often performed with infusion of dobutamine, a synthetic catecholamine with a variable effect on the α- and β-adrenoreceptors in the cardiovascular system (Tuttle and Mills, [@B50]; Barnett, [@B1]). In the healthy heart, the combined stimulation of these adrenoreceptors is expected to improve left ventricular contractility (inotropic effect), increase heart rate (chronotropic effect), and accelerate left ventricular relaxation (lusitropic effect). Hemodynamic responses to dobutamine are variable even amongst healthy subjects, but can include an increase in cardiac output and a decrease in total peripheral vascular resistance (Liang and Hood, [@B27]; Binkley et al., [@B3]; Parker et al., [@B36]).

Mathematical modeling to characterize left ventricular systolic and diastolic properties can incorporate the influence of multiple cardiovascular factors that contribute to the variable response to dobutamine among individual subjects. Mechanistic, physiologically based models permit data assimilation for identifying subject-specific parameters and estimating hemodynamic variables that are difficult to obtain non-invasively. Emerging imaging techniques have enabled characterization of the heart from anatomy to several functional measures including heart motion, myofiber architecture, blood flow, and even metabolism (Lamata et al., [@B26]). This has made possible to personalize three-dimensional models of cardiac biomechanics using invasive and/or non-invasive measurements from different modalities (Smith et al., [@B42]; Trayanova et al., [@B49]). In the context of assessing systolic and diastolic ventricular function such models can be applied to, for instance, generate left ventricular pressure-volume loops and ventricular pressures (Krishnamurthy et al., [@B25]) and to estimate regional cardiac contractility (Chabiniok et al., [@B8]).

Lumped parameter representations are often used as boundary conditions for higher dimensional models (Gurev et al., [@B19]), but can also be used individually to describe global hemodynamics (Heldt et al., [@B21]; Zhong et al., [@B57]; Ellwein et al., [@B14]). In this type of models, the contractility of the heart chambers is typically represented using a mathematical description of the time-varying elastance (Suga et al., [@B46]; Stergiopulos et al., [@B45]). Lumped parameter models are relatively simple and less computationally expensive than three-dimensional approaches, which makes them suitable for real-time simulation in the clinical setting.

In a previous study, we developed an approach combining non-invasive measurements, including three-directional three-dimensional cine phase-contrast magnetic resonance imaging (4D Flow MRI) data (Dyverfeldt et al., [@B11]), and a lumped parameter model of the cardiovascular system to obtain personalized parameters characterizing global hemodynamics (Casas et al., [@B7]). The model presented in our previous study, which includes the influence of the proximal aortic and peripheral vasculature, can more broadly represent the total cardiovascular response to changes in loading conditions, and potentially provide a more accurate estimate of load-independent contractility and relaxation parameters. However, this approach has so far been tested only in healthy subjects and its applicability under stress conditions has not yet been investigated.

In this work, we aim to investigate whether our modeling approach based on non-invasive data can be used to quantify, on an individual basis, changes in cardiovascular function during dobutamine stress, with particular focus on load-independent parameters of LV contractility and relaxation that conventionally require specialized invasive measurements. In addition, with this investigation we aim to test the applicability of the modeling approach beyond the resting operating conditions for which it was initially developed. This represents a key step toward assessing the usefulness of the developed approach in the clinical setting.

Materials and methods {#s2}
=====================

Study population
----------------

We personalized parameters in the computational model using non-invasive measurements from subjects without a known cardiovascular disease, acquired prior to and during the infusion of dobutamine. Inclusion criteria were no history of cardiovascular disease and no medication for cardiovascular disease. The exclusion criteria were arterial hypertension (values of arterial blood pressures ≥140/90 mmHg; Mancia et al., [@B30]), absence of normal ventricular size, wall thickness or wall motion based on the morphological balanced steady-state free precession (bSSFP) images at rest, acute coronary artery disease, severe aortic stenosis, hypertrophic obstructive cardiomyopathy and heart failure NYHA class superior to II. Reference values for the EDV (Maceira et al., [@B29]) were used to assess if subjects had normal ventricular size. Wall thickness and wall motion were visually assessed on the bSSFP images by a clinician with 15 years of experience in cardiovascular imaging. Fourteen subjects were enrolled in the study, although five subjects were excluded based on data quality. The resulting study group consisted of nine subjects (seven females), with an age of 29 ± 11 years (range 20--56 years), height 172 ± 9 cm (range 156--184 cm), and weight 67 ± 9 kg (range 52--85 kg).

The subjects were recruited using public advertisement on bulletin boards at the Linköping University Hospital. This study was carried out in accordance with the recommendations of the Regional Ethical Review Board in Linköping. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Regional Ethical Review Board in Linköping (Dnr 2014/114-31).

Study protocol
--------------

The subjects underwent an MRI protocol consisting of two acquisitions, one acquisition at rest and a second acquisition during the infusion of dobutamine. The dobutamine infusion protocol was initiated after the acquisition of 4D Flow MRI data performed at rest. Dobutamine was administered intravenously starting at a dose between 5 and 10 μg/kg/min, and the dose was increased or decreased in intervals of \~2 min depending on the observed effect on the subject\'s heart rate and arterial pressure. The target heart rate was 50% higher than the subject\'s rest heart rate, in order to achieve heart rates in the range of those from previous studies on stress testing with cardiac magnetic resonance (CMR) (Pennell et al., [@B37]; van Rugge et al., [@B52]; Roest et al., [@B38]; Steding-Ehrenborg et al., [@B44]). Heart rate was monitored continuously throughout the study. The blood pressures were measured at rest and during the administration of dobutamine, approximately every second minute, using a cuff sphygmomanometer. The dobutamine infusion was maintained until the scans in the second MRI acquisition were completed.

MRI examinations and data processing
------------------------------------

All MRI examinations were performed on a clinical 3T Philips Ingenia scanner (Philips Healthcare, Best, the Netherlands). During the examination, we acquired morphological cine bSSFP images and 4D Flow MRI data.

Morphological bSSFP images included three- and four-chamber long-axis (LAx) images and a stack of SAx images. During the scan performed after the infusion of dobutamine, only the three-chamber image and the SAx stack were acquired. The images were acquired during end-expiratory breath holds using the following settings: echo time 1.4 ms, repetition time 2.8 ms, flip angle 45° and slice thickness 8 mm. The bSSFP images were reconstructed into 30 time frames. The SAx images were reconstructed with a pixel size of 0.9 × 0.9 mm^2^ and the LAx images 0.83 × 0.83 mm^2^.

4D Flow MRI data were acquired during free breathing, using a navigator gated gradient-echo pulse sequence with interleaved three-directional flow-encoding and retrospective vector cardiogram controlled cardiac gating (Dyverfeldt et al., [@B12]; Eriksson et al., [@B16]). Sequence parameters were: velocity encoding (VENC) 140 cm/s, flip angle 5°, echo time 3.0 ms, repetition time 5.2 ms, parallel imaging (SENSE) speed up factors of 3 (AP direction) and 1.6 (RL direction), k-space segmentation factor 2 and elliptical k-space acquisition. The spatial resolution was 2.8 × 2.8 × 2.8 mm^3^ and the temporal resolution 41.6 ms. This resulted in a scan time of \~7--8 and 10--15 min excluding and including navigator efficiency, respectively, for a heart rate of 60 bpm. Following acquisition, the data were retrospectively reconstructed into 40 time frames and corrected for concomitant gradient fields on the scanner. Subsequently, the data were transferred to an offline station for post-processing and analysis. Post-processing was performed using in-house developed software written in Matlab (The Mathworks Inc., Natick, Massachusetts, USA). This included correction for background errors using a weighted second-order polynomial fit to static tissue in the thorax (Ebbers et al., [@B13]) and for phase wraps by the use of a temporal algorithm (Xiang, [@B56]).

Personalization of model parameters
-----------------------------------

### Lumped-parameter model of the cardiovascular system

We implemented a reduced version of our previous model of the heart and the systemic circulation (Casas et al., [@B7]), in order to focus on the physiology of the left ventricle and the systemic vasculature. The model used in this study included three compartments: the pulmonary venous system, the left side of the heart (including the left atrium, the mitral valve, the left ventricle, and the aortic valve) and the systemic arterial system. The model of the systemic arterial circulation was reduced to include the ascending aorta and a single compartment representing the vessels in the systemic circulation, down to the peripheral vascular bed. A schematic representation of the cardiovascular model is shown in Figure [1](#F1){ref-type="fig"}.

![Anatomical configuration and equivalent lumped parameter model of the cardiovascular system. **(A)** Anatomy of a representative subject shown as a 4D PC-MR angiogram at peak systole, including segmentations of anatomical regions of interest for the model: the left atrium (yellow), the left ventricle (red), and the aorta (blue). The analysis planes used for extracting subject-specific input flows for the model are located at the mitral valve (MV), aortic valve (AV), and ascending aorta (AA). **(B)** A schematic representation of the lumped parameter model. The building blocks corresponding to the different anatomical compartments are highlighted in dashed lines and color-coded according to the anatomical representation in **(A)** Descriptions of the parameters in the model can be found in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.](fphys-09-01515-g0001){#F1}

To characterize the contractile state of the heart chambers over the cardiac cycle, we used the concept of time-varying elastance formalized by Suga et al. ([@B46]). This is a well-established formulation to describe the filling and the contraction patterns of the chambers. The time-varying elastance relates chamber pressure and volume along the cardiac cycle, as given by:
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where *P*(*t*) is the chamber pressure and *V*(*t*) is the volume. *V*~*o*~ is the unstressed volume, defined as the volume-axis intercept of the end-diastolic relationship with the volume axis.

The shape of the elastance curve was approximated by a Double-Hill function (Stergiopulos et al., [@B45]; Mynard et al., [@B32]):
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where *T* is the cardiac cycle length, and *E*~max~ and *E*~min~ are the values of maximal and minimal elastance (i.e., stiffness of the chamber). For the left ventricle, *E*~max~ corresponds to the end-systolic elastance and *E*~min~ characterizes the passive diastolic elastance of the chamber. A representative cardiac elastance curve is illustrated in Figure [2](#F2){ref-type="fig"}. The dimensionless parameters α~*S*~, α~*D*~, *R*~*C*~, and *R*~*R*~ determine the shape of the curve within each cardiac period. The rate of chamber contraction, reflected as the slope of the ascending part of the curve, is represented by the parameter *R*~*C*~. Similarly, *R*~*R*~ corresponds to the rate of chamber relaxation (i.e., the steepness of the descending part of the curve). The systolic and diastolic time constants (τ~*S*~ and τ~*D*~, respectively) are defined as a function of *T* and the dimensionless shape parameters α~*S*~ and α~*D*~ (τ~*S*~ = α~*S*~ · *T* and τ~*D*~ = α~*D*~ · *T*). α~*S*~ and α~*D*~ determine the length of systole and diastole relative to each cardiac cycle each cardiac cycle, thereby controlling the time of end-systole (*t*~max~). An increase in α~*D*~ and/or a decrease in α~*s*~ yield an increase in *t*~max~ (i.e., a reduction of the duration of diastole), and vice versa. In the following, we refer to α~*S*~ and α~*D*~ as systolic and diastolic time constant shape parameters, respectively. The scaling factor α ensures a maximal elastance of *E*~max~.

![Schematic representation of the time-varying elastance curve, E(t), used to describe the heart chambers. The elastance values range from the end-systolic, maximal elastance (*E*~*max*~) to its minimal value (*E*~*min*~) over the duration of the cardiac cycle (T). The maximal elastance occurs at the time of end-systole (*t*~*max*~). The time instant zero corresponds to the onset of isovolumic contraction. The shape is determined by the ascending slope or contraction rate (*R*~*C*~), the descending slope or relaxation rate (*R*~*R*~) and the systolic (α~*s*~), and diastolic (α~*D*~) time constants. These constants determine the length of systole and diastole relative to the cardiac cycle duration (T), thereby controlling *t*~*max*~.](fphys-09-01515-g0002){#F2}

The pressure gradient across the aortic valve was modeled using the formulation of the net pressure gradient introduced by Garcia et al. ([@B17]), which takes into consideration the pressure recovery phenomenon (Baumgartner et al., [@B2]). Using this formulation, the pressure gradient is computed as a function of the transvalvular flow rate, the effective orifice area (EOA) of the valve and the cross-sectional area of the aorta. Pressure recovery was not considered at the mitral valve, as its effect on the transmitral pressure gradient is negligible in healthy subjects (Vandervoort et al., [@B53]).

Vessel segments in the systemic circulation were modeled using a combination of two resistances (*R* and *Rv*), a compliance (*C*), and an inductance (*L*). In each segment, the resistance *R* and the inductance *L* represent frictional losses and mass flow inertia, respectively, while the combination of compliance *C* and resistance *Rv* represent the viscoelastic properties of the vessel wall (Sun et al., [@B47]). The systemic vascular bed, down to the capillaries, was represented using a three-element viscoelastic Windkessel model (Burattini and Natalucci, [@B5]).

The model equations were implemented in Matlab Simscape 2017a (The Mathworks Inc., Natick, Massachusetts, USA). Details on the simulation settings for solving the model equations are described in Casas et al. ([@B7]).

### Subject-specific input measurements

For each subject in the study, we computed all model-based parameters at rest and following the infusion of dobutamine. These parameters were estimated based on subject-specific measurements acquired at rest and after dobutamine administration. The subject-specific inputs include the duration of the cardiac cycle, MRI-derived measurements characterizing the morphology and function of the left ventricle and the aortic valve, as well as volumetric flow waveforms from three selected sites in the systemic circulation. These three sites correspond to the mitral valve, the aortic valve and the ascending aorta, upstream from the brachiocephalic trunk (MV, AV, and AA in Figure [1](#F1){ref-type="fig"}, respectively). The analysis to obtain the MRI-derived input measurements was performed by a single observer. These imaging data were combined with non-invasive cuff systolic and diastolic pressure measurements in the brachial artery.

The length of the cardiac cycle (T) was derived as the average cardiac cycle duration throughout the 4D Flow MRI acquisition. Estimation of the left ventricular elastance requires computing the left ventricular end-systolic volume (LVESV). This volume was calculated by manual delineation of the endocardial border, including the papillary muscles, in the short-axis stack at the time of end systole. In estimating the EOA of the aortic valve, the stroke volume (SV) was computed by integrating the volumetric flow curve at the aortic valve over the entire cardiac cycle. The velocity-time integral of the transvalvular flow (VTI) was calculated using the instantaneous velocity at the center of the valve. The cross-sectional area of the aorta was measured at the time of peak systole, distal to the coronary artery ostia.

Transmitral (MV) and transaortic (AV) valvular flows were extracted using a semi-automatic retrospective valve tracking approach (Westenberg et al., [@B54]), in order to accurately locate the analysis plane based on the position of the valve annulus. The approach requires two manually placed input points to identify the valve annulus in the end-diastolic time frame. The analysis plane at the ascending aorta was placed manually, using a 4D PC-MR angiogram generated from the 4D Flow MRI data for anatomical orientation. The volume flow through each analysis plane was calculated by manual delineation of the valve orifice or the vessel contour for every time frame along the cardiac cycle (Stalder et al., [@B43]). Details on the calculation of the volumetric flow waveforms are given in Casas et al. ([@B7]).

Besides the subject-specific measurements involved in model personalization, we derived additional measurements characterizing peripheral hemodynamic responses to dobutamine infusion in each subject. The systemic vascular resistance (SVR) was computed as the mean arterial blood pressure (MAP) divided by the cardiac output (CO), as described elsewhere (Casas et al., [@B7]). The total systemic arterial compliance was calculated as the ratio between the SV and the pulse pressure (PP), computed as the difference between systolic blood pressure (SBP), and diastolic blood pressure (DBP) (Otsuki et al., [@B34]).

### Subject-specific parameter estimation

The cardiovascular model consists of 40 parameters. Of these parameters, 6 represent the pulmonary venous system, 20 characterize the heart chambers, 5 the heart valves and 7 the systemic vessels. The cardiac cycle length (T), and the density of blood (ρ) are also defined as parameters. Twenty three parameters were adjusted to be subject-specific, while the remaining 17 were defined based on literature values from previous studies (Sun et al., [@B47]; Heldt et al., [@B21]; Garcia et al., [@B18]; Mynard et al., [@B32]; Broomé et al., [@B4]). The parameters established according to literature along with their corresponding values are given in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The choice of parameters to be adjusted for personalization was based on the availability of *in vivo* measurements, as well as the results from the identifiability analysis performed in our previous study (Casas et al., [@B7]). In particular, structurally non-identifiable parameters and those describing the pulmonary vessels were set to literature values. Adjustable parameters were personalized based on measures derived from the *in vivo* data, or using nonlinear optimization to obtain the best agreement between the model-based and the measured flow waveforms. The number of parameters estimated using the nonlinear optimization routine was 20. A detailed description of the approach for tuning the subject-specific parameters, including the nonlinear optimization routine, is given in Casas et al. ([@B7]).

Image-processing tools
----------------------

The left ventricular segmentations were performed using the freely available segmentation software Segment version 1.9 (Medviso, Lund, Sweden) (Heiberg et al., [@B20]). The commercially available software Ensight (CEI Inc., NC, USA) was used for flow visualizations, creation of the 4D PC-MR angiograms and placement of the analysis planes at the locations of interest. Retrospective valve tracking and flow quantification at the analysis planes were carried out using in-house software written in Matlab (The Mathworks Inc., Natick, Massachusetts, USA).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS Statistics v.23.0 (IBM Corp., Armonk, NY, USA). We performed non-parametric Wilcoxon signed-ranked tests to assess the differences between variables at rest and under dobutamine stress. A *p* \< 0.05 was considered significant. All data are presented as mean ± standard deviation (SD).

Results {#s3}
=======

All subjects completed the study according to the protocol and no complications were seen in relation to the infusion of dobutamine. Across all subjects, the peak dose infused during the scan time was 15 ± 6 μg/kg/min (range 10--25 μg/kg/min). The maximal peak dose of 25 μg/kg/min was reached in two subjects. Table [1](#T1){ref-type="table"} presents demographic data and the dobutamine peak doses administered during the MRI examination for each subject in the study.

###### 

Demographic data and peak dobutamine doses during the MRI examination for all nine subjects in the study.

  **Subject number**   **Age range (years)**   **Weight range (kg)**   **Height range (cm)**   **Peak dose during the MRI examination (μg/kg/min)**
  -------------------- ----------------------- ----------------------- ----------------------- ------------------------------------------------------
  1                    30--39                  60--69                  170--179                15
  2                    20--29                  70--79                  180--189                10
  3                    20--29                  60--69                  170--179                10
  4                    20--29                  70--79                  170--179                25
  5                    20--29                  60--69                  160--169                12
  6                    20--29                  60--69                  170--179                12
  7                    20--29                  80--89                  170--179                25
  8                    30--29                  50--59                  150--159                10
  9                    50--59                  60--69                  160--169                15

*The age, weight, and height of each subject are presented as a range*.

MRI-derived indices of cardiovascular function
----------------------------------------------

Individual changes in heart rate (HR) and cardiac output (CO) induced by the infusion of dobutamine are shown in Figure [3](#F3){ref-type="fig"}. Dobutamine increased heart rate and cardiac output in all subjects, yielding significant differences from 66 ± 9 to 105 ± 19 beats/min (*p* = 0.008) and 5.6 ± 1 to 9.2 ± 1.7 l/min (*p* = 0.008), respectively (Table [2](#T2){ref-type="table"}).

![**(A)** Heart rate (HR) and **(B)** cardiac output (CO), as derived from the MRI measurements, at rest and following the infusion of dobutamine in the nine study subjects. Each subject is represented with different color, as indicated in the figure. A value of *p* \< 0.05 was considered significant.](fphys-09-01515-g0003){#F3}

###### 

MRI-derived indices of cardiac function extracted at rest and following the infusion of dobutamine.

                    **Rest**                      **Dobutamine**             ***p***
  ----------------- ----------------------------- -------------------------- ----------------------------------------
  HR (beats/min)    66 ± 9 (55--82)               105 ± 19 (76--127)         0.008[^\*^](#TN1){ref-type="table-fn"}
  CO (l/min)        5.6 ± 1(4.3--7.2)             9.2 ± 1.7 (7.2--11.6)      0.008[^\*^](#TN1){ref-type="table-fn"}
  SBP (mmHg)        115.5 ± 12.8 (98--137)        139.2 ± 19.9 (119--186)    0.013[^\*^](#TN1){ref-type="table-fn"}
  MAP (mmHg)        86.4 ± 10.2 (76.2--102.3)     98.3 ± 11 (87.1--117.8)    0.066
  DBP (mmHg)        66 ± 10.3 (56--85)            63.7 ± 8.1 (53--77)        0.48
  LVESV (mL)        70.3 ± 18.9 (45.4--103.6)     48.9 ± 24 (19--88.2)       0.015[^\*^](#TN1){ref-type="table-fn"}
  LVEDV (mL)        153.5 ± 27.9 (123.3--199.7)   141.8 ± 41.5 (81--217.5)   0.17
  SV (mL)           85.4 ± 14 (70.3--108.8)       88.9 ± 17.8 (59--118.5)    0.51
  EF (%)            56 ± 8 (47--71)               65 ± 10 (53--82)           0.066
  SVR (mmHg·s/mL)   0.97 ± 0.23 (0.69--1.46)      0.66 ± 0.14 (0.46--0.9)    0.008[^\*^](#TN1){ref-type="table-fn"}
  CT (mL/mmHg)      1.9 ± 0.52 (1.2--2.8)         2.1 ± 0.41 (1.3--2.6)      0.37

*Values are presented as mean ± standard deviation, with ranges given in parentheses. HR, heart rate; CO, cardiac output; SBP, systolic blood pressure; MAP, mean arterial pressure; DBP, diastolic blood pressure; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; SV, stroke volume; EF, ejection fraction; SVR, systemic vascular resistance; CT, total systemic arterial compliance*.

*p \< 0.05 vs. rest*.

Figure [4](#F4){ref-type="fig"} depicts individual changes with dobutamine in additional indices derived from the MRI data and the non-invasive cuff pressure measurements. The results are summarized in Table [2](#T2){ref-type="table"}. SBP increased significantly (Table [2](#T2){ref-type="table"}, Figure [4A](#F4){ref-type="fig"}), while non-significant changes were found for DBP and MAP (Table [2](#T2){ref-type="table"}, Figures [4B,C](#F4){ref-type="fig"}). Left ventricular ESV decreased significantly (Table [2](#T2){ref-type="table"}, Figure [4D](#F4){ref-type="fig"}). No significant differences were found in left ventricular EDV, SV, or EF (Table [2](#T2){ref-type="table"}, Figures [4E--G](#F4){ref-type="fig"}). Systemic vascular resistance (SVR) decreased significantly in response to dobutamine. On the contrary, no significant changes were seen in total systemic arterial compliance (Table [2](#T2){ref-type="table"}, Figures [4H,I](#F4){ref-type="fig"}).

![Arterial pressures, ventricular volumes, and systemic resistance and compliance at rest and following the infusion of dobutamine in the nine study subjects. Values are derived from the MRI data and the non-invasive cuff pressure measurements **(A--C)** show dobutamine-induced changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean aortic pressure (MAP), respectively. **(D--F)** illustrate changes in left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), and stroke volume (SV). Changes in ejection fraction (EF), systemic vascular resistance (SVR), and total arterial compliance are shown in **(G--I)**, respectively. Each subject is represented with a different color, as indicated in the figure. A value of *p* \< 0.05 was considered significant.](fphys-09-01515-g0004){#F4}

Model-based parameters and 4D flow MRI volumetric flow waveforms
----------------------------------------------------------------

Figure [5](#F5){ref-type="fig"} shows the measured and the model-based volumetric flow waveforms for a representative subject at baseline (Figures [5C,E,G](#F5){ref-type="fig"}) and following the infusion of dobutamine (Figures [5D,F,H](#F5){ref-type="fig"}). The subject-specific fitting was performed successfully in all nine subjects included in the study. At rest, the root mean square error (RMSE) between the measured and the model-based flow waveforms across the nine study subjects was 25 ± 6.6 ml/s at the mitral valve, 21 ± 5.1 ml/s at the aortic valve and 22.2 ± 4.9 ml/s at the ascending aorta. Under dobutamine stress, the RMSE values between the waveforms at these locations were 53 ± 18.5, 49.9 ± 22.7, and 37±13 ml/s, respectively. The RMSE values for every subject are listed in Supplementary Table [S2](#SM1){ref-type="supplementary-material"}. Analysis of the 4D Flow MRI-derived flow waveforms revealed a significant increase in early (E) peak flow with dobutamine, from 427.1 ± 88.2 to 534.7 ± 128.8 mL/s (*p* = 0.011). Dobutamine administration also increased the late (A) peak flow from 164.6 ± 45.5 to 266.4 ± 94.5 mL/s (*p* = 0.008). Furthermore, we observed that the E and A waves of the mitral flow waveform progressively merged with increasing heart rates, as illustrated in Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}. Across all subjects, there was no significant change in E/A ratio with dobutamine (2.9 ± 1.2 vs. 2.4 ± 1.6, *p* = 0.14). Supplementary Figure [S1](#SM1){ref-type="supplementary-material"} gives an overview of the mitral flow patterns, at rest and under dobutamine stress, for all nine subjects in the study. The peak flow at the aortic valve increased significantly from 405.4 ± 67.8 to 659.3 ± 86.6 mL/s (*p* = 0.008), as did the peak flow at the ascending aorta (366.8 ± 75.4 to 595.4 ± 94.7 mL/s, *p* = 0.008).

![Comparison between volumetric flow waveforms derived from the 4D Flow MRI data and model-based waveforms obtained after subject-specific fitting in one of the study subjects (subject 2). **(A,B)** show flow visualizations in the left heart and the ascending aorta. The visualizations in **(A,B)** correspond to the scans acquired at rest and following the infusion of dobutamine, respectively. Pathlines covering the complete heart cycle are overlaid onto three-chamber anatomical images. Pathlines are color-coded according to speed. The visualization includes the analysis planes used to extract the volumetric flow waveforms. **(C,E,G)** show a comparison between the measured (black) and the model-generated (blue) flow waveforms in the mitral valve (MV), the aortic valve (AV), and the ascending aorta (AA) at rest. Comparisons between estimated and measured flow waveforms after dobutamine administration for the same subject are shown in **(D,F,H)**.](fphys-09-01515-g0005){#F5}

The changes with dobutamine in the parameters describing the time-varying elastance are illustrated in Figure [6](#F6){ref-type="fig"}. There was a significant increase in left-ventricular maximal elastance (*E*~*max,\ LV*~) from 1.8 ± 0.5 to 4.7 ± 3.6 mmHg/mL (*p* = 0.013), as seen in Figure [6A](#F6){ref-type="fig"}. The passive left-ventricular elastance (*E*~*min,\ LV*~) did not change (*p* = 0.48; Figure [6B](#F6){ref-type="fig"}). Inotropic stimulation with dobutamine also increased significantly the rate of ventricular contraction, *R*~*C,\ LV*~, from 1.5 ± 0.3 to 2 ± 0.5 (*p* = 0.038; Figure [6C](#F6){ref-type="fig"}). In addition, dobutamine induced a significant acceleration in ventricular isovolumic relaxation, as indicated by the change in *R*~*R,\ LV*~, from 37.2 ± 6.9 to 46.1 ± 12 (*p* = 0.028; Figure [6D](#F6){ref-type="fig"})

![Model-based parameters characterizing the left ventricular time-varying elastance in the nine study subjects. Changes with dobutamine in maximal (*E*~*max,LV*~) and passive diastolic elastance of the left ventricle (*E*~*min,LV*~) are shown in **(A,B)**. Individual changes in parameters describing the shape of the elastance are given in **(C--F)**, as follows: **(C)** rate of ventricular contraction *R*~*C,LV*~, **(D)** rate of ventricular relaxation *R*~*R,LV*~, **(E)** ventricular systolic time constant shape parameter α~*S,LV*~, and **(F)** ventricular diastolic time constant shape parameter α~*D,LV*~. Each subject is represented with a different color, as indicated in the figure. A value of *p* \< 0.05 was considered significant.](fphys-09-01515-g0006){#F6}

The increase in heart rate due to dobutamine infusion resulted in shortening of both the systolic and diastolic phases, with a moderately greater reduction in the duration of diastole in relation to systole. The percentage of diastolic duration relative to the cardiac cycle length was calculated based on the time of end-systole (*t*~*max*~), extracted from the estimated time-varying elastance curve. Among all subjects, the decrease in this percentage was between 1 and 10%, with larger decreases in the diastolic contribution associated with higher heart rates. Shortening of diastole in relation to the cardiac cycle length was reflected in the elastance timing parameters by a significant increase in the diastolic time constant shape parameter, α~*D,\ LV*~, from 0.4 ± 0.05 to 0.5 ± 0.05 (*p* = 0.008; Figure [6F](#F6){ref-type="fig"}). This resulted in a decrease of the elastance diastolic time constant from 0.4 ± 0.04 s to 0.3 ± 0.03 s (*p* = 0.008). Analysis of model-based parameters characterizing the vascular system revealed a non-significant increase in the compliance of the ascending aorta, *C*~*aa*~, from 0.11 ± 0.06 to 0.16 ± 0.1 mL/mmHg (*p* = 0.11).

Discussion {#s4}
==========

We evaluated a previously developed imaging-modeling approach for quantification of load-independent parameters of LV contractility and relaxation. An advantage of this approach is that it allows the estimation of physiological parameters, which typically require invasive measurements, in a non-invasive fashion. The evaluation was performed on a cohort of nine subjects without a known heart disease, both at rest, and under stress conditions induced by the infusion of dobutamine. Our results indicate that the approach is suited for both description of the experimental data and determination of parameters characterizing LV systolic and diastolic function across a physiologically relevant range of heart rates and loading conditions. This demonstrates that our approach has the ability to describe operating conditions for which it was not originally developed and serves to validate the realism of the model. This is therefore a key stepping stone toward eventual clinical implementation.

Several studies have investigated the effects of clinically induced stress on cardiovascular function based on non-invasive indices derived from Doppler ultrasound or 2D PC-MRI measurements, such as left ventricular volumes and mitral inflow patterns. In line with our results, these studies have reported a decrease in left ventricular ESV (Steding-Ehrenborg et al., [@B44]), enhanced mitral peak E and A flows (el-Said et al., [@B15]; Kilner et al., [@B24]; Paelinck et al., [@B35]). In addition, like others (Kilner et al., [@B24]; Chung et al., [@B9]; Paelinck et al., [@B35]), we found a progressive merging of mitral E and A waves as a result of increasing heart rates during stress conditions.

The model-based parameters revealed subject-specific increases in contractility as indicated by the increase in rate of left ventricular contraction under stress conditions, as well as an enhancement of diastolic function by faster early relaxation. The latter was demonstrated by an increase in the rate of left ventricular relaxation. These results are consistent with previous studies reporting an increase in these parameters based on invasive measurements (Karliner et al., [@B23]; Little et al., [@B28]; Myreng and Smiseth, [@B33]; Udelson et al., [@B51]). Similar to previous observations from mitral inflow patterns (Kilner et al., [@B24]; Paelinck et al., [@B35]), the systolic and diastolic time constant shape parameters derived from the elastance function indicate the shortening of diastolic length at higher heart rates. One of the study participants (subject 9) exhibited a response to dobutamine with changes in hemodynamic variables different from the average changes observed in the study group, as seen in Figure [4](#F4){ref-type="fig"}. For this specific subject, the elastance model parameters revealed a decrease in both maximal ventricular elastance and the relaxation rate. These results contrast with the behavior of the parameters found in the rest of study subjects. A possible explanation for this discrepancy is the presence of ventricular dysfunction, which was unmasked at the higher rates achieved with the stress protocol.

In the present study, we estimated the maximal elastance of the left ventricle using a single-beat approach, assuming a volume intercept of 10 mmHg as defined in previous studies (Mynard et al., [@B32]). Alternatively, this assumption can be avoided by using single-beat methods that involve approximation of the pre-ejection period to total systolic period. These methods have been shown to provide a better estimation of the maximal elastance, as measured by conventional pressure- volume measurements with varying loading conditions (Senzaki et al., [@B40]), including variations in inotropic state and different cardiovascular diseases. In our study, a volume intercept of 10 mmHg might result in some overestimation of the actual maximal elastance considering the decreased LVESV values with dobutamine, and therefore this should be taken into consideration when interpreting the results from the model. Accurate estimations of the time-varying elastance also require precise measurements of the LVESV. Currently, CMR is considered the gold standard for measuring ventricular volumes with regard to reproducibility and accuracy (Danilouchkine et al., [@B10]). The left ventricular segmentations performed in this study were based on short-axis morphological images, a well-validated approach (Sievers et al., [@B41]) that is generally incorporated into the clinical CMR protocol. To avoid inaccuracies in the estimated LVESV, the short-axis images acquired during the stress protocol were examined and acquisition was repeated, if necessary, to ensure sufficient image quality.

Our results showed no significant differences between passive diastolic compliance at rest and during stress. Schmitt et al. ([@B39]) reported an increase with dobutamine in diastolic compliance, calculated as an exponential fit of the EDPVR measured using combined catheter and CMR measurements in swine. A possible explanation for this discrepancy could be the definition of passive diastolic compliance used in the current study. While the ESPVR can be regarded as relatively linear, the EDPVR is known to be inherently nonlinear (Burkhoff et al., [@B6]). In this context, the constant passive compliance described by the time-varying elastance implies a linear EDPVR, thereby leading to inaccuracies in the estimated value. In contrast, in the same study, Schmitt et al. ([@B39]) showed no differences in diastolic compliance with dobutamine in patients with a single ventricle. The validity of our results should be assessed in future studies by comparison with invasive pressure measurements, possibly acquired in patients that undergo catheterization as part of the clinical routine.

Limitations
-----------

The current study has several limitations besides the ones mentioned in our previous publication (Casas et al., [@B7]). A major limitation is the lack of invasive measurements for validation of the estimated model-based parameters. This would require acquiring a family of pressure-volume loops by the use of catheter measurements during the infusion of dobutamine simultaneous to the CMR scan and was considered beyond the scope of the study. A second limitation is related to the uncertainty in the input measurements to the model. Our approach relies on non-invasive measurements of blood pressure and assumes the absence of both noise in the 4D Flow MRI data and potential errors derived from the analysis (i.e., inter- and intra- observer variability). Further studies are needed to assess how these potential sources of error might affect the uncertainty of the model-derived parameters. Nevertheless, given the trends in the parameters and the sufficiently large differences between the parameter values at rest and under dobutamine stress, we consider that these potential errors do not affect the validity of our results.

The study only included a limited number of subjects. This limits the statistical power of the study and the extrapolation of our results. This should therefore be taken into consideration when interpreting the statistical significance of the results. Nevertheless, the study group displays a broad range of physiologically relevant loads and heart rates, and the changes in parameters were significant despite the low total study population. Additional studies including a larger number of subjects should be conducted to confirm the clinical relevance of the statistical significances reported in the current work.

In addition, we only evaluated the changes in parameters with stress in subjects without known cardiovascular disease. The analysis of these parameters in subjects with a spectrum of diseases, such as ischemic heart disease, valvular disorders, and heart failure is subject to further studies. Those studies should focus on assessing the added value of these parameters over conventional image-derived parameters in diagnosing and optimizing the treatment of the disease.

Conclusions {#s5}
===========

The integrated imaging-modeling approach used in this study provided subject-specific parameter values that behaved appropriately, according to previously reported effects of dobutamine on cardiovascular function, across a physiologically relevant range of loads and heart rates. With further validation, the approach could be used to assess these parameters, which are difficult to obtain non-invasively in clinical practice, thereby complementing conventional non-invasive indices used in the assessment of ventricular function. Future validation studies should preferably involve comparison to invasive measurements and application on larger populations, including both healthy subjects, and patients representing a spectrum of cardiovascular diseases. The personalized assessment may have the potential to generate advanced metrics of cardiovascular physiology and pathophysiology that could extend beyond conventional techniques for both diagnosis and optimization of a personalized medical regimen.
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bSSFP

:   Balanced Steady-State Free Precession

CMR

:   Cardiac Magnetic Resonance

DBP

:   Diastolic Blood Pressure

CO

:   Cardiac Output

EDPVR

:   End-Diastolic Pressure-Volume Relationship

EOA

:   Effective Orifice Area

ESPVR

:   End-Systolic Pressure-Volume Relationship

EDV

:   End-diastolic volume

EF

:   Ejection fraction

ESV

:   End-systolic volume

LV

:   Left Ventricular

MAP

:   Mean Arterial Pressure

NYHA

:   New York Heart Association

PC

:   Phase-Contrast

PP

:   Pulse Pressure

RMSE

:   Root mean square error

SBP

:   Systolic Blood Pressure

SENSE

:   Sensitivity Enconding

SV

:   Stroke Volume

SVR

:   Systemic Vascular Resistance

VENC

:   Velocity Encoding

VTI

:   Velocity-Time Integral.
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